The Pathogenic Role of Low Range Repeats in SCA17

• Published in: PloS one Vol. 10; no. 8; p. e0135275
• Main Authors: Shin, Jung Hwan, Park, Hyeyoung, Ehm, Gwan Hee, Lee, Woong Woo, Yun, Ji Young, Kim, Young Eun, Lee, Jee-Young, Kim, Han-Joon, Kim, Jong-Min, Jeon, Beom Seok, Park, Sung-Sup
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 12.08.2015; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Ataxia; Autopsies; Autopsy; Basal ganglia; Brain diseases; Case-Control Studies; Central nervous system diseases; Cerebellar ataxia; Cerebellum; Chorea; Chromosomes; Dementia; Deoxyribonucleic acid; Disorders; DNA; Dyskinesias - genetics; Dystonia; Female; Genetics; Hospitals; Humans; Huntingtons disease; Male; Medicine; Middle Aged; Movement disorders; Neurobiology; Neurology; Neurosciences; Parkinson's disease; Parkinsons disease; Patients; Polyglutamine; Proteins; Range extension; Statistical analysis; TATA-binding protein; TATA-Box Binding Protein - genetics; Tbp gene; Trinucleotide repeat diseases; Trinucleotide Repeat Expansion; Trinucleotide repeats; South Korea
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0135275

SCA17 is an autosomal dominant cerebellar ataxia with expansion of the CAG/CAA trinucleotide repeats in the TATA-binding protein (TBP) gene. SCA17 can have various clinical presentations including parkinsonism, ataxia, chorea and dystonia. SCA17 is diagnosed by detecting the expanded CAG repeats in the TBP gene; however, in the literature, pathologic repeat numbers as low as 41 overlap with normal repeat numbers. The subjects in this study included patients with involuntary movement disorders such as cerebellar ataxia, parkinsonism, chorea and dystonia who visited Seoul National University Hospital between Jan. 2006 and Apr. 2014 and were screened for SCA17. Those who were diagnosed with other genetic diseases or nondegenerative diseases were excluded. DNA from healthy subjects who did not have a family history of parkinsonism, ataxia, psychiatric symptoms, chorea or dystonia served as the control. In total, 5242 chromosomes from 2099 patients and 522 normal controls were analyzed. The total number of patients included in the analysis was 2099 (parkinsonism, 1706; ataxia, 345; chorea, 37; and dystonia, 11). In the normal control, up to 44 repeats were found. In the 44 repeat group, there were 7 (0.3%) patients and 1 (0.2%) normal control. In 43 repeat group, there were 8 (0.4%) patients and 2 (0.4%) normal controls. In the 42 repeat group, there were 16 (0.8%) patients and 3 (0.6%) normal controls. In 41 repeat group, there were 48 (2.3%) patients and 8 (1.5%) normal controls. Considering the overlaps and non-significant differences in allelic frequencies between the patients and the normal controls with low-expansions, we could not determine a definitive cutoff value for the pathologic CAG repeat number of SCA17. Because the statistical analysis between the normal controls and patients with low range expansions failed to show any differences so far, we must consider that clinical cases with low range expansions could be idiopathic movement disorders showing coincidental CAG/CAA expansions. Thus, we need to reconsider the pathologic role of low range expansions (41-42). Long term follow up and comprehensive investigations using autopsy and imaging studies in patients and controls with low range expansions are necessary to determine the cutoff value for the pathologic CAG repeat number of SCA17.